EEBA Program (PDF/3MB) - EEBA - Annual Meeting

USE OF ANTI-VEGF (BEVACIZUMAB) AFTER PENETRATING KERATOPLASTY (PK) FORHERPETIC KERATITISM. Ratković, M. Pauk Gulić, N. Miličić, I. DekarisSpecial Eye Hospital Svjetlost, Department of Ophthalmology, School of Medicine in Rijeka, University of Rijeka, CroatiaPurpose: To improve corneal graft survival rate after PK for herpetic keratitis by bevacizumabtreatment combined with conventional therapy.Methods: Prospective study of 15 eyes with postherpetic corneal scar which underwent PK: 6 malecaucasian eyes (average age 48,67 years), and 9 female caucasian eyes (average age 54,45 years). Allpatients underwent PKP surgery ended by subconjunctival bevacizumab injection (25 mg/ml), localand systemic acyclovir and conventional postgraft treatment. Grafts were prospectively (average 20months; range:6-36) examined for clearance and presence of neovascularization (NV).Results: 93.3% of corneal grafts remained clear at the end of the observation period. BCVAimprovement was from 0.062 (range: light perception – 0.25) to 0.62 (range 0.3 – 1.0); 28% of eyes hadhigh postoperative astigmatism (> 5 diopter, range 5 – 10) , 7% IOP elevation, 14,2% had recidivantherpes infection on transplant, 21% had cataract formation, 21% had graft reaction.Conclusions: Addition of subconjunctival bevacizumab injection to convencional therapy after PK forherpetic keratitis improves the survival rate in our practice up to 93.3%.XXV ANNUAL MEETING OF THE EUROPEAN EYE BANK ASSOCIATION Zagreb, Croatia 18/19 January 2013 67